{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:55:54Z","timestamp":1759341354020,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10067-016-3273-2","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T04:05:00Z","timestamp":1461038700000},"page":"2045-2051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase\/URAT1 dual inhibitor PF-06743649"],"prefix":"10.1007","volume":"35","author":[{"given":"Pinky","family":"Dua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Gurrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sudworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Loudon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"issue":"10","key":"3273_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, FitzGerald JD, Khanna PP et al (2012) American college of rheumatology guidelines for management of gout part I: systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64(10):1431\u20131446. doi: 10.1002\/acr.21772","journal-title":"Arthritis Care Res"},{"issue":"4","key":"3273_CR2","first-page":"287","volume":"59","author":"RW Watts","year":"1966","unstructured":"Watts RW (1966) Uric acid production with particular reference to the role of xanthine oxidase and its inhibition. Proc R Soc Med 59(4):287\u2013292","journal-title":"Proc R Soc Med"},{"issue":"6","key":"3273_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"M Becker","year":"2009","unstructured":"Becker M, Schumacher H, Macdonald P, Lloyd E, Lademacher C (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. The J Rheumatol 36(6):1273\u20131282. doi: 10.3899\/jrheum.080814","journal-title":"The J Rheumatol"},{"issue":"3","key":"3273_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/14656566.2015.985588","volume":"16","author":"M Bridgeman","year":"2015","unstructured":"Bridgeman M, Chavez B (2015) Febuxostat for the treatment of gout. Expert Opin Pharmacother 16(3):395\u2013398. doi: 10.1517\/14656566.2015.985588","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"3273_CR5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000000035","volume":"26","author":"M Bach","year":"2014","unstructured":"Bach M, Simkin P (2014) Uricosuric drugs. Curr Opin Rheumatol 26(2):169\u2013175","journal-title":"Curr Opin Rheumatol"},{"unstructured":"ClinicalTrials.gov [Internet]. Identifier: NCT 02187029 Efficacy, safety and Tolerability of PF-06743649 in Gout Subjects. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02187029","key":"3273_CR6"},{"unstructured":"Shimizu K (2008) Japan.[Patent] WO2008126898A1.Available at: http:\/\/www.google.com.ar\/patents\/WO2008126898A1?cl\u2009=\u2009en","key":"3273_CR7"},{"unstructured":"ClinicalTrials.gov [Internet]. Identifier: NCT 02151617 A study in Healthy people to Evaluate Saftey, Toleration, pharmacokinetics And Pharmacodynamics of multiple Oral Dose Of PF-06743649. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02151617","key":"3273_CR8"},{"unstructured":"ClinicalTrials.gov [Internet]. Identifier: NCT 02170012 A study in Healthy Elderly people to Evaluate Saftey, Toleration, pharmacokinetics And Pharmacodynamics of multiple Oral Dose Of PF-06743649. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02170012","key":"3273_CR9"},{"issue":"3","key":"3273_CR10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallance","year":"1977","unstructured":"Wallance SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20(3):895\u2013900","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3273_CR11","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh L, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner J, Baumgartner S (2014) Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hypercuricaemia. Rheumatology 53(12):2167\u20132174","journal-title":"Rheumatology"},{"key":"3273_CR12","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"M Becker","year":"2005","unstructured":"Becker M, Schumacher H, Wortmann R, Schumacher R, MacDonald P, Eustace D, Palo W, Streit J, Ridge N-J (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med 353:2450\u20132461. doi: 10.1056\/NEJMoa050373","journal-title":"New Engl J Med"},{"issue":"8","key":"3273_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/jama.1980.03300340042018","volume":"243","author":"H Sawa","year":"1980","unstructured":"Sawa H, Yamakawa H, Renjel L, Fernandes M (1980) Acute renal failure during treatment with ticrynafen. JAMA 243(8):766\u2013767. doi: 10.1001\/jama.1980.03300340042018","journal-title":"JAMA"},{"unstructured":"NDA 207988: Lesinurad for the proposed indication of treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor Edited by (FDA) FaDA. Arthritis Advisory Committee Meeting (2015) http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM467942.pdf","key":"3273_CR14"},{"issue":"8","key":"3273_CR15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"MH Lee","year":"2008","unstructured":"Lee MH, Graham GG, Williams KM, Ro D (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was it withdrawal from the marker in the best interest of patients? Drug Saf 31(8):643\u2013665","journal-title":"Drug Saf"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3273-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3273-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:59:31Z","timestamp":1559105971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3273-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3273"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3273-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}